IV Iron Superior to Oral for Anemia in Pregnancy: Study

For pregnant women battling iron deficiency anemia, a new body of evidence suggests a significant advantage for intravenous (IV) ferumoxytol over traditional oral iron supplements. While oral iron remains a common first-line treatment, research indicates that IV ferumoxytol can more effectively improve hemoglobin levels and resolve anemia during pregnancy, potentially reducing risks for both mother and child.

The Challenge of Iron Deficiency in Pregnancy

Anemia during pregnancy is a widespread concern, affecting an estimated 37 percent of pregnant individuals globally, according to the World Health Organization. It’s often caused by iron deficiency and is linked to increased risks of preterm labor, hemorrhage, and even maternal and infant mortality. Iron is crucial for fetal development, particularly brain growth, and maternal iron deficiency can have long-term implications for the child’s health. Current guidelines typically recommend daily oral iron supplements, with IV iron considered for cases where oral iron isn’t sufficient, often in the third trimester.

Ferumoxytol: A New Approach to IV Iron

Ferumoxytol is a formulation of iron oxide designed for intravenous administration. Unlike older IV iron formulations that require multiple visits for complete replenishment, ferumoxytol allows for the delivery of a complete dose in a single infusion, or at most two. This convenience factor is a significant benefit for patients, reducing the burden of repeated clinic visits. The formulation’s structure – superparamagnetic iron oxide linked to polyglucose sorbitol carboxymethylether – allows for a tighter binding of elemental iron, facilitating efficient administration.

Recent Findings: Efficacy and Safety

A study presented at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting in January 2025, conducted across multiple sites in India with 4,368 participants, demonstrated that a single dose of IV ferumoxytol administered early in the second trimester was both safe and effective in treating anemia during pregnancy. This is particularly noteworthy given the high prevalence of anemia in India. Earlier research, published in Therapeutic Advances in Hematology in May 2021, also supported the efficacy and safety of ferumoxytol in pregnant women with iron deficiency anemia, reporting significant improvements in hemoglobin and iron parameters without any reported adverse events. The 2021 study involved 131 consecutive, non-selected pregnant women in the second and third trimesters.

Understanding the Study Limitations

While these studies are promising, it’s important to acknowledge their limitations. The large Indian study, while significant in size, was conducted in a specific population with a high baseline prevalence of anemia. The results may not be directly generalizable to populations with different ethnic backgrounds or dietary habits. The 2021 study, with a smaller sample size, focused specifically on women receiving ferumoxytol twice or once, and did not include a control group receiving oral iron. It’s difficult to definitively state the superiority of ferumoxytol over oral iron based on this study alone. Further research, including randomized controlled trials comparing ferumoxytol directly to oral iron in diverse populations, is needed.

What Does This Indicate for Pregnant Women?

These findings don’t necessarily mean that all pregnant women with iron deficiency anemia should immediately switch to IV ferumoxytol. Oral iron remains a viable option, particularly for those with mild anemia who tolerate it well. Although, the evidence suggests that IV ferumoxytol may be a more effective choice for women who are not responding to oral iron, experiencing significant side effects from oral iron (such as gastrointestinal distress), or require rapid iron repletion. The decision about which treatment is best should be made in consultation with a qualified healthcare provider, taking into account individual circumstances and risk factors.

The Importance of Early Intervention

The Indian study’s focus on administering IV iron early in the second trimester is significant. Traditionally, IV iron has been reserved for the third trimester when anemia is often more severe. However, the research suggests that earlier intervention may be more effective in preventing the negative consequences of iron deficiency anemia for both mother and baby. The developing fetal brain is particularly vulnerable to iron deficiency, and ensuring adequate iron levels throughout pregnancy is crucial for optimal neurological development.

The Future of Anemia Treatment in Pregnancy

The growing body of evidence supporting the use of IV iron, particularly formulations like ferumoxytol, is likely to influence obstetric guidelines in the future. The SMFM study highlights the need for a reevaluation of current practices and a consideration of earlier IV iron intervention for pregnant women at risk of or diagnosed with iron deficiency anemia. Ongoing research will continue to refine our understanding of the optimal timing, dosage, and patient selection criteria for IV iron therapy in pregnancy. Further trials are needed to confirm these findings in diverse populations and to assess the long-term effects of early IV iron intervention on both maternal and infant health. Clinicians will likely be watching for updates from organizations like the American College of Obstetricians and Gynecologists (ACOG) regarding potential changes to their recommendations.